Research Article
Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
Table 1
Demographics and general clinical data of all studied patients.
| | Parameters | DC-CIK group n = 53 | Control group n = 53 | value |
| | Gender (male/female) | 33/20 | 27/26 | 0.327 |
| | Age (years) | 61.55 ± 9.08 | 63.10 ± 9.19 | 0.384 |
| | Tumor location | | | 0.782 | | Cardia of the stomach | 6 (11.3%) | 5 (9.4%) | | | Fundus of the stomach | 14 (26.4%) | 16 (30.2%) | | | Body of the stomach | 15 (28.3%) | 12 (22.6%) | | | Antrum of the stomach | 18 (15.1%) | 20 (37.7%) | |
| | Pathological type | | | 0.686 | | Well-differentiated adenocarcinoma | 9 (17.0%) | 11 (20.8%) | | | Moderately differentiated adenocarcinoma | 22 (41.5%) | 19 (35.8%) | | | Poorly differentiated adenocarcinoma | 17 (32.1%) | 19 (35.8%) | | | Mucinous adenocarcinoma | 5 (9.4%) | 4 (7.5%) | |
| | TNM staging | | | 0.693 | | IIIA | 14 (26.4%) | 16 (30.2%) | | | IIIB | 23 (43.4%) | 24 (45.3%) | | | IIIC | 16 (30.2%) | 13 (24.5%) | |
| | ECOG (points) | | | 0.508 | | 0 | 18 (34.0%) | 15 (28.3%) | | | 1 | 25 (47.2%) | 23 (43.4%) | | | 2 | 10 (18.9%) | 15 (28.3%) | |
|
|
Notes. DC-CIK: dendritic cell-cytokine-induced killer cells; TNM: tumor, lymph node, metastasis; ECOG: eastern cooperative oncology group.
|
